Readers have filed corrections to previous postings on industry-funded studies (see here and here). I am most grateful for their sharp eyes. No excuses, but I’m having a hard time keeping them straight because there are so many, some are published first online and then again in print, and sometimes I just get them wrong. Apologies.
The corrections reduce the count to 132/12. But here are three more to bring it back up to 135/12.
Management of obesity. George A Bray, Gema Frühbeck, Donna H Ryan, John P H Wilding. The Lancet. Published online February 8, 2016 http://dx.doi.org/10.1016/S0140-6736(16)00271-3.
Conclusion: For patients who struggle with weight loss and who would receive health benefit from weight loss, management of medications that are contributing to weight gain and use of approved medications for chronic weight management along with lifestyle changes are appropriate. Medications approved in the USA or European Union are orlistat, naltrexone/bupropion, and liraglutide; in the USA, lorcaserin and phentermine/topiramate are also available. Surgical management (gastric banding, sleeve gastrectomy, and Roux-en Y gastric bypass) can produce remarkable health improvement and reduce mortality for patients with severe obesity.
Declaration of interests GAB is a consultant to Herbalife International and Medifast; a member of the Speakers Bureau for Novo Nordisk Pharmaceuticals and Takeda Pharmaceuticals; and receives royalties fro…